All stock lists
Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
Healthcare · Biotechnology
1.28+0.00 (+0.39%)
Insider Score
––Not scored
CDXS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
CDXS analyst forecast
CDXS analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CDXS 12-month price target
No published price targets in the last 12 months.
Best analysts covering CDXS
- Piper Sandler25%success rate · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CDXS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-08-17 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-11-22 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-11-15 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-29 |
| — | Benchmark | Hold | — | — | Downgraded | 2024-08-19 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-09 |
| — | Benchmark | Buy | — | — | Reiterated | 2024-05-03 |
| — | Benchmark | Buy | — | — | Upgraded | 2024-02-29 |
| — | Benchmark | Hold | — | — | Downgraded | 2023-11-07 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-11-06 |
| — | Benchmark | Buy | — | — | Reiterated | 2023-09-01 |
| — | Stifel | Buy | — | — | Reiterated | 2023-08-14 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2023-07-21 |
| — | HC Wainwright & Co. | Neutral | — | — | Downgraded | 2023-05-09 |
| — | Benchmark | Buy | — | — | Reiterated | 2023-05-09 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-04-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-02-27 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-01-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-11-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-08-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-07-18 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2022-07-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-07-15 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2022-05-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-10-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-08-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-06-18 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2021-04-12 |
| — | Stifel | Buy | — | — | Reiterated | 2021-03-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-02-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-05-11 |
| — | First Analysis | Outperform | — | — | Upgraded | 2019-01-17 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2018-06-19 |
| — | Jefferies | Buy | — | — | Reiterated | 2017-10-13 |
| — | Jefferies | Buy | — | — | Reiterated | 2017-05-31 |
| — | First Analysis | Equal Weight | — | — | Downgraded | 2017-01-26 |
| — | Ladenburg Thalmann | Buy | — | — | Upgraded | 2017-01-04 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2016-01-06 |
| — | Ladenburg Thalmann | Neutral | — | — | Downgraded | 2015-03-04 |
| — | Sidoti & Co. | Neutral | — | — | Reiterated | 2013-04-09 |
| — | Piper Sandler | Neutral | — | — | Upgraded | 2012-09-05 |
| — | PiperJaffray | Neutral | — | — | Upgraded | 2012-09-05 |
| — | Piper Sandler | Underweight | — | — | Reiterated | 2012-08-10 |
| — | Credit Suisse | Neutral | — | — | Downgraded | 2012-08-10 |
| — | PiperJaffray | Underweight | — | — | Reiterated | 2012-08-10 |
| — | Piper Sandler | Underweight | — | — | Reiterated | 2012-05-11 |
| — | PiperJaffray | Underweight | — | — | Reiterated | 2012-05-11 |
| — | Piper Sandler | Underweight | — | — | Downgraded | 2012-02-21 |
| — | PiperJaffray | Underweight | — | — | Reiterated | 2012-02-21 |
CDXS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-11 | 0.01 | 0.11 | $35.8M | $38.9M |
| 2026-05-07 | -0.11 | -0.10 | $14.5M | $15.2M |
| 2026-08-11 | -0.14 | -0.13 | $13.8M | $14.9M |
| 2026-11-05 | -0.09 | 0.00 | $18.7M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.